Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as anti prolactin receptor humanized monoclonal antibody
LFA102 · 2 trials · 4 indications
Frequency and severity of dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| LFA102 | EXPERIMENTAL | - |
| Breast & Prostate Cancer Group | EXPERIMENTAL | Dose Escalation |
| Breast Cancer Group | EXPERIMENTAL | Dose Expansion |
| Prostate Cancer Group | EXPERIMENTAL | Dose Expansion |
| Uterine Leiomyoma Group | EXPERIMENTAL | Dose Expansion |
| Name | Type | Description |
|---|---|---|
| LFA102 | DRUG | - |
Inclusion Criteria: * Histologically confirmed diagnosis of prostate cancer * Histologically or cytologically confirmed locally advanced or metastatic breast cancer Exclusion Criteria: * Patients with untreated and/or symptomatic metastatic CNS disease * Prior anaphylactic or other severe infusio...
LFA102 is an investigational small molecule being studied for the treatment of castration-resistant prostate cancer and advanced or metastatic breast cancer. It was evaluated in patients with prolactin receptor-positive tumors, including castration-resistant prostate cancer and metastatic breast cancer.
LFA102 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is in clinical development for oncology indications.
LFA102 is in Phase 1 clinical development. Two Phase 1 studies have been completed, one in patients with prolactin receptor-positive castration-resistant prostate cancer or metastatic breast cancer and another in Japanese patients with castration-resistant prostate cancer or advanced breast cancer.
LFA102 has been studied in two completed Phase 1 clinical trials. The first, NCT01338831, enrolled 73 patients with prolactin receptor-positive castration-resistant prostate cancer or metastatic breast cancer across the United States, Belgium, Italy, and Spain. The second, NCT01610050, enrolled 14 Japanese patients.
LFA102 is an investigational drug studied in patients with prolactin receptor-positive tumors. It was evaluated in clinical trials for castration-resistant prostate cancer and advanced or metastatic breast cancer, conditions where prolactin receptor expression was present in the tumors.